The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Understanding breast cancer – The long and winding road
Open accessAbstract
BACKGROUND: Despite a remarkable increase in the depth of our understanding and management of breast cancer in the past 50 years, the disease is still a major public health problem worldwide and poses significant challenges. The palpability of breast tumors has facilitated diagnosis and documentation since ancient times. The earliest descriptions of breast cancer date back to around 3500 BCE. For centuries to follow, theories by Hippocrates (460 BCE) and Galen (200 CE), attributing the cause of breast cancer to an "excess of black bile" and treatment options including the use of opium and castor oil, prevailed. Surgical resection was introduced in the 18th century. The advent of modern medicine led to the development of novel treatment options that include hormonal, targeted and chemo-therapies. There are still several therapeutic challenges including the treatment of triple negative breast cancer (TNBC), and overcoming drug resistance. SCOPE OF REVIEW: The increased incidence and awareness of breast cancer has led to significant changes in diagnosis and treatment in recent decades. But, mankind has come a long way. Herein, I have traced how our understanding of breast cancer has evolved from the early description of the disease around 460 BCE as "black bile-containing crab-like tumors" to the conventional as a heterogeneous disease with high degree of diversity between and within tumors, as well as among breast cancer patients. How is breast cancer treated today and how do risk factors, breast cancer subtype and drug resistance contribute to the therapeutic challenges at the turn of the 21st century? MAJOR CONCLUSIONS: Breast cancer remains a serious public health issue worldwide. However, appreciable growth in our understanding of breast cancer in the past century has led to remarkable progress in the early detection, treatment and prevention of the disease. The clinical focus is shifting more towards tailored therapy as more targets are characterized and novel highly innovative approaches are developed. GENERAL SIGNIFICANCE: Tracing the history of breast cancer, highlights how increased awareness of the disease, and progress in research and development have enhance our understanding of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · cited 1×
“However, two discoveries in the ‘90s that had a great impact on diagnosis and care were: 1) the identification in 1994 of specific inherited mutations in tumor suppressor genes BRCA1 and BRCA2 that increased the risks of breast and ovarian cancers (Reviewed in [44]); and 2) the development of the first targeted anti-b…”
Background
Cited by
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer
Sharma, P., Mehta, M., Dhanjal, D. S., Kaur, S., Gupta, G., Singh, H., Thangavelu, L., Rajeshkumar, S., Tambuwala, M., Bakshi, H. A., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.06.033 · Cited by 430
Ruiz, A., van Hillegersberg, R., Siesling, S., Castro-Benitez, C., Sebagh, M., Wicherts, D. A., de Ligt, K. M., Goense, L., Giacchetti, S., Castaing, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.024 · Cited by 84
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer
Kumar, N., Gulati, H. K., Sharma, A., Heer, S., Jassal, A. K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., et al. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10133-y · Cited by 37
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
Bhat, V., Pellizzari, S., Allan, A. L., Wong, E., Lock, M., Brackstone, M., Lohmann, A. E., Cescon, D. W., & Parsyan, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103566 · Cited by 31
Metadata
- Authors
- Lukong, K. E.
- Venue
- BBA Clinical
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 7
- Pages
- 64-77
- ISSN
- 2214-6474 (ISSN-L)
- OpenAlex
- W2581091741
- Cited by
- 232
- References
- 6
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding breast cancer – The long and winding road. https://app.cochat.ai/papers/10.1016/j.bbacli.2017.01.001
- The paper
- Lukong, K. E. (2017). Understanding breast cancer – The long and winding road. BBA Clinical. https://doi.org/10.1016/j.bbacli.2017.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.